finacialnews-logo-final-01 (2).png
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
18 déc. 2024 08h45 HE | FN Media Group LLC
PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by...
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
17 déc. 2024 08h00 HE | Immuneering Corporation
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
17 déc. 2024 08h00 HE | Cargo Therapeutics, Inc.
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Qu Biologics.png
Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor
16 déc. 2024 08h00 HE | Qu Biologics, Inc.
BURNABY, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
medicenna.jpg
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
13 déc. 2024 08h30 HE | Medicenna Therapeutics Corp.
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse...
cgoncology_cover.jpg
CG Oncology Announces Pricing of Public Offering
12 déc. 2024 20h19 HE | CG Oncology Inc.
CG Oncology Announces Pricing of Public Offering
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
12 déc. 2024 08h00 HE | Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
cgoncology_cover.jpg
CG Oncology Announces Proposed Public Offering
11 déc. 2024 06h17 HE | CG Oncology Inc.
CG Oncology Announces Proposed Public Offering
YourUpdateTV speaks with Northwestern Mutual Foundation: Northwestern Mutual Awards 50 Scholarships to Childhood Cancer Survivors and Siblings to Help Fund Higher Education
10 déc. 2024 10h00 HE | D S Simon
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Every day, more than 1,000 children worldwide are diagnosed with cancer—a life-changing moment for families. Recently, Steve Radke, president of the...
Radiographic Response over Time* - as of November 26, 2024
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
10 déc. 2024 06h00 HE | Cardiff Oncology, Inc.
- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control...